OVERVIEW OF WGNV

The Working Group on New TB Vaccines (WGNV) was established in 2001. It is one of the nine Working Groups of the Stop TB Partnership.

The mission of the WGNV is to facilitate research and development (R&D) of new TB vaccines by providing an inclusive forum for stakeholders to engage in scientific exchange, foster discussion, and advocate for greater support and investment in TB vaccine R&D.

The WGNV is an informal network of stakeholders engaged in all aspects of TB vaccine R&D and from all constituencies, including academics, product developers, clinicians, advocates, and affected communities. Membership is open to anyone who is interested in being engaged and involved in TB vaccine R&D.

OVERVIEW OF WGNV CORE GROUP

The WGNV Core Group (CG) is responsible for ensuring the effectiveness of the WGNV by setting strategic direction, identifying priority areas of work, and engaging in WGNV activities. CG members are the foundation of the WGNV and must be willing/able to devote time to WGNV activities.

The CG is expected to:

• Oversee and engage in the activities of WGNV
• Monitor progress of WGNV activities
• Assist WGNV Chair in addressing strategic and operational issues
• Actively participate in at least one WGNV activity/priority per grant year
• Meet regularly as required, primarily by videoconference
• Collaborate with and consult other Stop TB WGs, Partnership Secretariat, and partners on cross-cutting issues
• Serve as an independent, technical, expert advisory group where required by the Stop TB Partnership and partners
• Ability to work in written and spoken English
• Regular access to internet, email, and phone service

All Core Group members should demonstrate the following:

• Experience working in partnerships
• Ability to be an effective representative of their constituency group in WGNV discussions, activities, and planning
• Commitment to increasing the visibility of TB vaccine R&D in the overall TB and public health agenda
• Willingness and ability to play a leadership role in developing and advancing the activities strategies of the WGNV that fall within their area(s) of expertise

WGNV CG members are expected to contribute a minimum of two (2) hours per month, although actual time per month will vary based on activities. This time is not compensated.

Affected Communities Representative

The Affected Communities Representative position on the WGNV Core Group brings the perspective of people and communities affected by TB to the Core Group and to WGNV strategic planning. The Affected Communities Representative will lead efforts to make the WGNV an inviting platform for this constituency and will present idea for activities and programs that would increase engagement by and provide support for affected communities in WGNV and TB vaccine R&D. The term for this position is two years.

In addition to the expectations of all Core Group members as noted above, the Affected Communities Representative should meet the following additional criteria:

• Has been impacted by TB
• From a TB high-burden country
• Actively engaged in TB advocacy
• Demonstrated interest in TB vaccine research and research advocacy
• Willingness and ability to assist WGNV in engaging with affected communities to share information and resources, and to expand affected community membership in the WGNV and its activities.

Representatives from affected communities who are interested in being considered for this position on the WGNV Core Group should submit a CV and a letter of interest by 30 September 2023 to wgnv@iavi.org.

Applications will be reviewed by the WGNV Core Group, and the Core Group will select the Affected Communities Representative.

Download PDF version